After a product reaches the market, Phase IV studies provide long-term safety and effectiveness data in real-world settings. These studies may be required by regulatory agencies or initiated by sponsors to gather evidence on rare adverse events, usage patterns, or health outcomes over time.
In cardiovascular medicine, real-world evidence is essential for market access, payer support, and clinical adoption, especially for innovative therapies, high-risk devices, or breakthrough diagnostics.
Turn long-term data into lasting market value. SCIRENT helps you stay ahead with real-world insights that matter.
We are a specialized cardiovascular CRO with a deep understanding of the regulatory, clinical, and operational landscape. Whether you’re developing a novel device, diagnostic, or drug – we bring the expertise, network, and flexibility you need at every stage of development.
